| Document Date: 2012-11-16 16:34:17
Open Document File Size: 522,24 KBShare Result on Facebook
City CAMBRIDGE / AMSTERDAM / / Company Regenesance BV / Biogen Idec / ALS Therapy Development Institute Partners / ALS TDI / / Country United States / Netherlands / / Event Business Partnership / Product Issues / / Facility Center of Collaboration May / ALS Therapy Development Institute / / IndustryTerm therapeutics for neurodegenerative diseases / treatment of this disease / treatment for the disease / treatment of acute neurological disorders / / MedicalCondition progressive neurodegenerative disease / paralysis / Lou Gehrig’s disease / disease / ALS / chronic neurological indications / aggressive and rapid disease / amyotrophic lateral sclerosis / Traumatic Brain Injury / acute neurological disorders / Multiple Sclerosis / neurodegenerative diseases / neurodegenerative disorders / Myasthenia Gravis / / Organization MDA / RGK Foundation / ALS Therapy Development Institute / Center of Collaboration / / Person Frank Baas / Steve Perrin / Lou Gehrig / / Position CEO / / Product complement activation / / ProvinceOrState Massachusetts / / Technology drug development / / URL www.als.net / www.regenesance-pharma.com / /
SocialTag |
The ALS Therapy Development Institute Partners with Regenesance BV to Investigate Potential Treatments for Lou Gehrig’s Disease Complement Pathway Modulation at Center of Collaboration May 7, [removed]CAMBRIDGE & AMSTERD